Seoulin Bioscience
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SeouLinBioscience supplies the reagents, instruments, and consumables that biotech and pharmaceutical companies need to research, develop, and manufacture biological medicines, including cell therapies, gene therapies, antibody drugs, vaccines, and biosimilars.
Its customers range from basic life-science research labs to biopharmaceutical developers at every stage from early research through clinical trials and commercial production. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the overwhelming majority of its revenue from this bio-industry supply business, with smaller operations in hygiene and sterilisation solutions, AI-assisted bio-analysis services, and medical aesthetics run through a subsidiary.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates a subsidiary, Staron Medical (formerly Seorin Medicare), that runs a separate medical aesthetics business alongside the core bio-supply operations.
Seoulin Bioscience in five facts
What does Seoulin Bioscience do?
SeouLinBioscience supplies the reagents, instruments, and consumables that biotech and pharmaceutical companies need to research, develop, and manufacture biological medicines, including cell therapies, gene therapies, antibody drugs, vaccines, and biosimilars.
Where is Seoulin Bioscience listed and in which sector?
Seoulin Bioscience (Korean name: 서린바이오) trades under KRX code 038070 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Trading & Distribution.
How large is Seoulin Bioscience?
Its market capitalisation was US$27.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Seoulin Bioscience's latest annual revenue and operating profit?
For fiscal year 2025, Seoulin Bioscience reported revenue of US$58.2M, operating profit of US$522K and net income of US$433K, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 2.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
Seoulin Bioscience declared a cash dividend of US$0.07 per share, equal to about 1.5% of the recent share price.
Dividend · Mar 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Seoulin Bioscience reported consolidated results for FY2025: revenue of US$52.8M (+2.2% year on year), operating profit of US$473K (−27.4% year on year) and net income of US$393K (−81.7% year on year).
Earnings · Mar 5